• Explore /
  • Poster
  • / Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial.

Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial.

Abstract Poster

Authors

Nicholas Vogelzang

Nicholas J. Vogelzang

Comprehensive Cancer Centers of Nevada, Las Vegas, NV

Nicholas J. Vogelzang , Svein Inge Helle , Dag Clement Johannessen , Joe M. O'Sullivan , Jose E. Garcia-Vargas , C. Gillies O'Bryan-Tear , Minghua Shan , Chris Parker

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT00699751

Citation

J Clin Oncol 31, 2013 (suppl; abstr 5068)

DOI

10.1200/jco.2013.31.15_suppl.5068

Abstract #

5068

Poster Bd #

39C

Abstract Disclosures

Similar Posters

Poster

2015 Genitourinary Cancers Symposium

Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP).

Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP).

First Author: Nicholas J. Vogelzang

First Author: Simon J. Crabb

First Author: Bertrand F. Tombal

First Author: Michael J. Morris